Here is how NIH defines precision medicine.
My point is - AVXL has not identified yet which patients are more likely to have better results by A2-73. They selected all patients in one size fits all manner. So there is nothing precision about this trial.
They may find that the PDD trial is not successful for entire population but after doing sub-group analysis, they may find that some sub-group can be benefited by the drug. At that time, they will need to carry new trial and enroll only the sub-group to confirm that the sub-group really has the benefit. At that time it will become precision medicine approach trial.
In summary - the current trial is just like any other standard trial - nothing special. Let’s get good results so SP increases else we tank.
“What is precision medicine?
According to the Precision Medicine Initiative, precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person."
This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.
It is in contrast to a one-size-fits-all approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.”
Market Data 
Markets 
AI
